Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinoic acid-inducible gene I (RIG-I), encoded by the DDX58 gene, is a cytosolic pattern recognition receptor (PRR) and DExD/H-box RNA helicase that plays a critical role in the host innate immune response. It primarily senses short, double-stranded RNA (dsRNA) and single-stranded RNA containing a 5'-triphosphate or 5'-diphosphate moiety, which are characteristic of viral replication intermediates but absent in healthy host cells. Upon ligand binding, RIG-I undergoes a conformational change that exposes its N-terminal caspase activation and recruitment domains (CARDs), enabling homooligomerization and interaction with the mitochondrial antiviral-signaling protein (MAVS). This interaction initiates a signaling cascade that activates transcription factors IRF3, IRF7, and NF-κB, driving the production of type I and type III interferons and pro-inflammatory cytokines.
In addition to its role in antiviral defense, RIG-I activation triggers immunogenic cell death preferentially in cancer cells and remodels the tumor microenvironment, making it a highly attractive target for cancer immunotherapy. Conversely, aberrant or constitutive activation of RIG-I due to gain-of-function mutations is associated with autoimmune and autoinflammatory disorders, such as Singleton-Merten syndrome and lupus nephritis, where RIG-I inhibitors or downstream JAK inhibitors are being explored as therapeutic strategies.
RIG-I agonists mimic viral double-stranded RNA (dsRNA) with 5'-triphosphate ends, binding to the helicase and C-terminal domains of RIG-I. This induces a conformational change that exposes the N-terminal caspase activation and recruitment domains (CARDs), allowing interaction with mitochondrial antiviral-signaling protein (MAVS). This triggers downstream signaling via TBK1 and IKKε, activating IRF3, IRF7, and NF-κB, which leads to the production of type I/III interferons and pro-inflammatory cytokines, as well as immunogenic cell death in cancer cells. RIG-I inhibitors block the ATPase activity or RNA-binding of RIG-I to suppress aberrant interferon signaling.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinoic acid-inducible gene I (RIG-I).